Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper
{{output}}
CDK4/6 inhibitors plus endocrine therapy is a standard therapy for HR+/HER2- breast cancer. Herein, using structure-based drug design strategy, a novel series of palbociclib derivatives were designed and synthesized as CDK4/6 inhibitors, among which compound 1... ...
